Author | Silva, Gilberto Marcelo Sperandio da | |
Author | Mediano, Mauro Felippe Felix | |
Author | Hasslocher-Moreno, Alejandro Marcel | |
Author | Holanda, Marcelo Teixeira de | |
Author | Sousa, Andrea Silvestre de | |
Author | Sangenis, Luiz Henrique Conde | |
Author | Brasil, Pedro Emmanuel Alvarenga Americano do | |
Author | Arteaga Mejía, Roger | |
Author | Fux, Carina Perotti | |
Author | Cubides, Juan Carlos | |
Author | Saraiva, Roberto Magalhães | |
Author | Brum-Soares, Lucia Maria | |
Access date | 2023-05-24T01:39:30Z | |
Available date | 2023-05-24T01:39:30Z | |
Document date | 2017 | |
Citation | SILVA, Gilberto Marcelo Sperandio da et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease. Journal of Antimicrobial Chemotherapy, v. 72, n. 9, p. 2596-2601, Sept. 2017. | en_US |
ISSN | 0305-7453 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/58601 | |
Sponsorship | This study was supported by the international medical humanitarian organization Me´decins Sans Frontie`res (MSF) and the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil, Programa Estrate gico de Apoio a Pesquisa em Saude (Papes VII)/Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Brazil (grant 401878/ 2015–5 to G. S. d. S.). | en_US |
Language | eng | en_US |
Publisher | Oxford University Press | en_US |
Related document | https://www.arca.fiocruz.br/handle/icict/34210 | en_US |
Rights | open access | en_US |
Title | Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease | en_US |
Type | Article | en_US |
DOI | 10.1093/jac/dkx180 | |
Abstract | Background: Up to half of patients with Chagas’ disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment. Objectives: To verify the incidence and possible factors associated with the suspension of benznidazole treatment in a large cohort of patients. Methods: We included 2075 patients treated with benznidazole during the projects managed by the medical humanitarian organization Doctors Without Borders (Me´decins Sans Frontie`res) in Bolivia from 2009 to 2013. Benznidazole treatment was provided two or three times per day for 60 days at 5–7.5 mg/kg/day. A multiple logistic regression model was developed to evaluate the factors associated with permanent suspension of benznidazole treatment. Results: Permanent benznidazole treatment suspension occurred in 211 patients (10.2%) and the average time until permanent treatment suspension was 23 days. Multifactorial analysis revealed that female sex (adjusted OR " 1.70), moderate ADRs (adjusted OR " 10.57), mild ADRs (adjusted OR " 1.69) and skin disorders (adjusted OR " 4.18) were significantly associated with the permanent suspension of benznidazole treatment. Women with mild or moderate skin ADRs presented a probability of treatment interruption of 18.6% and 59.0%, respectively. Conclusions: Benznidazole treatment was safe and a large proportion of patients were able to complete a full course of benznidazole treatment under close treatment surveillance. Female sex, skin disorders and mild and moderate ADRs were independently associated with the permanent suspension of benznidazole treatment. In particular, women with moderate skin ADRs had the highest risk of benznidazole treatment interruption. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Médecins Sans Frontières. Operational Center Barcelona. Barcelona, Spain. | en_US |
Affilliation | Médecins Sans Frontières. Operational Center Barcelona. Barcelona, Spain. | en_US |
Affilliation | Médecins Sans Frontières. Brazilian Medical Unit. Rio de Janeiro, RJ, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Médecins Sans Frontières. Brazilian Medical Unit. Rio de Janeiro, RJ, Brazil. | en_US |
Subject | Benznidazole | en_US |
Subject | Médecins Sans Frontières | en_US |
Subject | Bolivian patients | en_US |
Subject | Chagas disease | en_US |